About velmanase alfa
Recombinant human alpha-mannosidase enzyme
Used for
- Long-term enzyme replacement therapy for non-neurological symptoms of alpha-mannosidosis.
Usual adult dose
Adults: 1 mg/kg by intravenous infusion once weekly.
Usual dose in children
Children: 1 mg/kg by intravenous infusion once weekly; approved from age 6 months.
Common side effects
- Infusion-related reactions
- Headache
- Fever
- Nausea
Important warnings
- Administer under healthcare supervision; serious allergic reactions can occur.
- Monitor for infusion reactions during and after treatment.
- It does not treat neurological symptoms of alpha-mannosidosis.
Pregnancy
Human pregnancy data are limited; use only when clinically necessary.
Breastfeeding
It is unknown whether velmanase alfa passes into breast milk; clinical data are limited.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.